Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

  • Kambiz Rahbar
  • Matthias Weckesser
  • Hojjat Ahmadzadehfar
  • Michael Schäfers
  • Lars Stegger
  • Martin Bögemann
Image of the Month

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;  https://doi.org/10.1007/s00259-017-3711-7.
  2. 2.
    Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.  https://doi.org/10.1007/s00259-016-3573-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity Hospital MuensterMünsterGermany
  2. 2.Department of Nuclear MedicineUniversity Hospital BonnBonnGermany
  3. 3.Department of UrologyUniversity Hospital MuensterMünsterGermany

Personalised recommendations